YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Key Points Interested in Virtus LifeSci Biotech Clinical Trials ETF? Here are five stocks we like better. ETFs like BBC, IWC, and GDXJ offer diversified exposure to high-risk sectors such as clinical-stage biotech, micro-caps, and junior g…
Key Points Interested in Virtus LifeSci Biotech Clinical Trials ETF? Here are five stocks we like better. ETF inflows hit $1 trillion in the first half of 2026, though many investors still favor major index-tracking funds over niche strate…
The biotech industry has held up well this year despite macroeconomic uncertainty, pricing pressures and regulatory challenges. Strong first-quarter earnings, new drug approvals and encouraging clinical trial updates have kept investor sen…
* Virtus LifeSci Biotech Clinical Trials ETF (BBC [https://seekingalpha.com/symbol/BBC]) - $0.6554 [https://www.virtus.com/products/bioshares-biotechnology-clinical-trials-etf#shareclass.619/period.monthly]. * Payable Dec 29; for sharehold…
For Immediate Release Chicago, IL – November 25, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial…
Wall Street was downbeat last week. The S&P 500 index lost 1.95%, the Dow Jones index retreated 1.9% and the Nasdaq Composite slumped 2.7%. Overvaluation concerns in the artificial intelligence (AI) space continued to hurt the space. NVIDI…
Wall Street delivered a mixed performance last week, with the S&P 500 adding 0.1%, the Dow Jones advancing 0.3% and the Nasdaq Composite losing about 0.5%. However, the Nasdaq Composite bounced back on Friday as investors returned to major…
Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to date, IBB has risen 18.2% versus SPY’s 17…
The U.S.-China trade tensions once again started hitting headlines since last Friday. On Friday, Trump announced plans to impose an additional 100% tariff on Chinese goods starting Nov. 1, in response to Beijing’s new export controls on ra…
For Immediate Release Chicago, IL – September 10, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financia…
Wall Street delivered a subdued performance last week. The S&P 500 advanced about 0.3%, the Dow Jones lost about 0.3% and the Nasdaq 100 gained 1%. The Alphabet-led tech rally and Fed rate cut hopes boosted the growth segment. Below, we hi…
NEW YORK, June 16, 2017 (GLOBE NEWSWIRE) -- LifeSci Index Partners, LLC, an affiliate company of LifeSci Advisors, and a New York City-based investment advisor and index provider, today announced the completion of its semi-annual rebalanci…
NEW YORK, May 15, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors today announced that Paul Yook, General Partner, LifeSci Venture Partners, will moderate the opening panel at MedCity INVEST, taking place this year from May 17–18, in Chicago, IL…
NEW YORK, Dec. 16, 2016 (GLOBE NEWSWIRE) -- LifeSci Index Partners, LLC (“LSIP”), a New York City-based investment advisor and index provider, today announced the completion of its semi-annual rebalancing and recomposition for its BioShare…
NEW YORK, June 16, 2016 (GLOBE NEWSWIRE) -- LifeSci Index Partners, LLC (“LSIP”), a New York City-based investment advisor and index provider, today announced the completion of its semi-annual rebalancing and recomposition for its BioShare…
NEW YORK, Dec. 16, 2015 (GLOBE NEWSWIRE) -- LifeSci Index Partners, LLC (“LSIP”), a New York City-based investment advisor and index provider, today announced the completion of its semi-annual rebalancing and recomposition for its BioShare…